Mizuho Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and increased the price target from $35 to $40, indicating a positive outlook on the company's stock.
December 29, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Uy Ear reaffirmed a Buy rating on ACADIA Pharmaceuticals and raised the price target to $40, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's stock, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100